32 stories found
Efforts to develop a vaccine for the current Ebola outbreak in the Democratic Republic of Congo have shown initial success, attributed to an innovative funding strategy, despite no approved vaccine or treatment being available for the Bundibugyo strain.
The Ervebo vaccine has proven safe and effective against the common Zaire strain of the Ebola virus, with early data suggesting it may also protect against the rarer Bundibugyo strain, potentially leading to public availability in DR Congo.
A new vaccine targeting the Bundibugyo strain of the Ebola virus, which has been devastating the Democratic Republic of the Congo, has begun human clinical trials.
The University of Oxford has officially launched the first human trial for a vaccine specifically targeting the Bundibugyo strain of Ebola, marking a critical step in global efforts to combat the deadly virus. This trial represents a significant advancement in developing defenses against this particular strain.
The Ebola outbreak in the Democratic Republic of Congo has claimed over 200 lives, with confirmed cases increasing by nearly 40% in a week. Health officials warn the outbreak is far from under control, and there are no vaccines for the current Bundibugyo strain.
Reakcja na pojawienie się wirusa ebola była spóźniona - ocenił szef Afrykańskich Centrów Kontroli i Zapobiegania Chorobom. W Demokratycznej Republice Konga i w Ugandzie przybywa zakażeń.
The World Health Organization has released updated figures, indicating 906 suspected cases and 223 suspected deaths attributed to the Bundibugyo strain of Ebola.
Russia has announced the development of a vaccine against the new Bundibugyo strain of the Ebola virus. Health Minister Murashko stated that Russian scientists achieved this breakthrough.
Research and development efforts are currently underway to create specific vaccines and treatments for the Bundibugyo strain of the Ebola virus.
The World Health Organization declared a global public health emergency over the rapidly spreading Ebola outbreak in the Democratic Republic of Congo, which has caused numerous deaths and prompted international concern. The outbreak has spread beyond borders, leading to increased intervention efforts and travel advisories.
International health experts have gathered to explore and identify potential vaccine options for the Ebola Bundibugyo strain, aiming to advance global efforts in combating the deadly virus.
The Democratic Republic of Congo has received 70,000 doses of the Ervebo vaccine to combat the rapidly spreading Ebola outbreak. However, the World Health Organization noted that these doses are not approved for the specific Bundibugyo strain currently prevalent in the region.
Moderna has initiated the first human trial for its vaccine targeting the Bundibugyo strain of the Ebola virus.
The World Health Organization (WHO) has initiated the first clinical trial for an antiviral medication specifically designed to prevent the Bundibugyo strain of Ebola. This marks a significant step in combating this particular variant of the virus.
Oxford University has initiated the first human trial for a vaccine targeting the Bundibugyo strain of the Ebola virus, marking a significant step in vaccine development.
The Nigeria Centre for Disease Control (NCDC) has appealed to state governors to boost funding for health workers to prevent the Bundibugyo strain of Ebola from entering the country.
Research and development efforts are currently focused on creating vaccines and treatments specifically for the Bundibugyo strain of the Ebola virus.
The African Union has announced that a new vaccine specifically targeting the Bundibugyo strain of Ebola is expected to be available by the end of this year. This development offers significant hope in the fight against the deadly virus.
Chinese researchers have developed an Ebola vaccine using mRNA technology, similar to that used for Covid-19. Animal trials have shown the vaccine to be effective against the currently devastating Bundibugyo strain.
An Ebola outbreak is causing increased concern due to a suspected undercount of cases. Meanwhile, the World Health Organization announced that an approved vaccine for the rare Bundibugyo strain is still several months from availability.
An informational piece delves into what is known about the Bundibugyo strain of the Ebola virus, providing details on its characteristics and impact.
Scientists have developed an experimental vaccine that successfully protected mice against three species of Ebola, including the Bundibugyo strain. New studies reveal the Bundibugyo strain is less lethal than the Zaire strain, killing 30% to 40% of infected people, while the vaccine still requires human testing.
Research has begun on a vaccine for the Bundibugyo strain of the Ebola virus. This comes as the Ebola epidemic in the Democratic Republic of Congo has become the deadliest in the country's history.
The first human trial for an experimental vaccine targeting the Bundibugyo strain of Ebola has commenced, with a volunteer in the UK receiving the initial dose. This development comes as Ebola cases in DR Congo continue to rise, reaching 2,905.
Oxford University has initiated the first human trials for a vaccine targeting the Bundibugyo strain of the Ebola virus. This comes as the majority of new Ebola cases in eastern Congo are from unknown chains, indicating the outbreak is outpacing the response.
Clinical trials have commenced in the Democratic Republic of Congo, focusing on the Bundibugyo strain of Ebola. The trials are taking place in the epicenter of the outbreak, marking a significant step in combating the disease.
Scientists are aiming to begin human trials for a new Ebola vaccine candidate against the deadly Ebola Bundibugyo strain within months, following a surge in funding.
The World Health Organization (WHO) reported a significant increase in suspected Ebola cases and deaths from the Bundibugyo strain, particularly in the Democratic Republic of Congo. The WHO chief visited the epicenter and announced prioritization of clinical trials for treatments and vaccines.
India has developed and is implementing RT-PCR tests specifically designed to detect the Bundibugyo strain of the Ebola virus, enhancing its diagnostic capabilities for this particular variant.
The World Health Organization has declared the Ebola risk in the Democratic Republic of Congo to be at its highest level, as the outbreak continues to spread rapidly. Health workers are struggling to contain the virus, prompting the UN to allocate $60 million and send additional personnel to the region.
An Ebola outbreak in the Democratic Republic of Congo has claimed over 130 lives, prompting deep concern from the World Health Organization over its scale and speed. The virus continues to spread, leading to international travel alerts and fears among the affected population.
Recent explainers detail the current knowledge surrounding the Bundibugyo strain of the Ebola virus. These reports aim to inform the public about this specific variant of the deadly disease.